Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...

Medically reviewed by Jamin Brahmbhatt, MD IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system ...

Many medical problems, such as traumatic brain injuries, stroke, dementia, and even cancer, can affect the brain and make it difficult for someone to think or process information. Cognitive ...

SaveHealth reports on managing type 2 diabetes through medications, lifestyle changes, and support, highlighting various ...